PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-20.40%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-19.78%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
12.20%
EPS growth under 50% of CRVO's 28.96%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
12.20%
Diluted EPS growth under 50% of CRVO's 28.96%. Michael Burry would worry about an eroding competitive position or excessive dilution.
35.62%
Share count expansion well above CRVO's 23.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
35.62%
Diluted share count expanding well above CRVO's 23.15%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-10.71%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-10.88%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-812.85%
Negative 10Y OCF/share CAGR while CRVO stands at 99.97%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
87.84%
5Y OCF/share CAGR at 75-90% of CRVO's 99.17%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
86.67%
3Y OCF/share CAGR at 75-90% of CRVO's 98.69%. Bill Ackman would press for improvements in margin or overhead to catch up.
-1279.04%
Negative 10Y net income/share CAGR while CRVO is at 99.98%. Joel Greenblatt sees a major red flag in long-term profit erosion.
88.03%
5Y net income/share CAGR at 75-90% of CRVO's 99.28%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
86.27%
Positive short-term CAGR while CRVO is negative. John Neff would see a clear advantage in near-term profit trajectory.
1371.24%
Positive growth while CRVO is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-83.09%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-60.87%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.71%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-34.03%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-19.69%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
7.98%
R&D dropping or stable vs. CRVO's 44.38%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
58.15%
SG&A growth well above CRVO's 44.86%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.